Researchers at the University of Illinois recently re-engineered small molecules to disrupt toxic RNA repeats involved in DM2.
Exciting news out of Washington, DC: the House of Representatives' Energy & Commerce Committee ordered the MD-CARE Act to advance to the House floor!
The DMCRN was established a little over a year ago to evaluate potential DM treatments, prepare possible clinical trial sites and conduct important DM research studies.
Dr. Darren Monckton is an internationally-known DM researcher who provides valuable information to the MDF community. Check out his videos and upcoming webinar that will explore the significance of CTG repeats for people with DM and how to understand blood test results.
Researchers identify the gene believed to be responsible for adverse statin drug side effects in DM2 patients.